<div id="readability-page-1"><div><ul> <li>On 12 January 2026, AbbVie and RemeGen announced an exclusive licensing agreement for RC148, a PD-1/VEGF-targeted bispecific antibody, giving AbbVie rights outside Greater China in exchange for a US$650 million upfront payment plus very large potential milestone payments and tiered, double-digit royalties.</li> <li>This deal not only validates RemeGen’s immuno-oncology platform, but also ties its future RC148 opportunity to AbbVie’s global ADC and solid tumor portfolio.</li> <li>We’ll now examine how this extensive AbbVie partnership around RC148 could reshape RemeGen’s investment narrative and long-term oncology positioning.</li> </ul><p>Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.</p><h2>What Is RemeGen's Investment Narrative?</h2><p>To own RemeGen today, you really have to believe in its ability to turn a broad, loss‑making pipeline into durable, commercial oncology and autoimmune franchises. The AbbVie deal around RC148 is a clear swing factor in that story: the US$650 million upfront meaningfully extends the cash runway and reduces balance sheet risk in the near term, while shifting one of RemeGen’s key solid‑tumor assets into a global partnership model. In the short run, the main catalysts now cluster around RC148’s development progress with AbbVie and late‑stage readouts and filings for telitacicept and DV, rather than any buyback activity, which has been a non‑event so far. The flip side is that execution risk, high valuation multiples and dependence on a few lead programs become even more central to the equity case.</p><p> However, one business risk in particular is easy to underestimate at first glance.  RemeGen's shares have been on the rise but are still potentially undervalued by 14%. Find out what it's worth.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/earnings-and-revenue-growth"/><figcaption>SEHK:9995 Earnings &amp; Revenue Growth as at Jan 2026</figcaption></figure> <p>Simply Wall St Community members currently offer 1 fair value view around HK$114.07 for RemeGen, showing how even a single detailed model can differ from market pricing. Set against the AbbVie RC148 deal and RemeGen’s still‑meaningful losses, that community input underlines how different investors can weigh partnership upside versus execution and concentration risks, which you should consider alongside professional estimates.</p><p>Explore another fair value estimate on RemeGen - why the stock might be worth just HK$114.07!</p><h2>Build Your Own RemeGen Narrative</h2><p>Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your RemeGen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.</li><li>Our free RemeGen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate RemeGen's overall financial health at a glance.</li></ul><h2>Seeking Other Investments?</h2><p>Our top stock finds are flying under the radar-for now. Get in early:</p><ul><li>These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.</li><li>Uncover the next big thing with financially sound penny stocks that balance risk and reward.</li><li>The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

ABBV

688331

09995

<p>On January 12, 2026, AbbVie and RemeGen entered an exclusive licensing agreement for RC148, a bispecific antibody, with AbbVie paying $650 million upfront. This partnership enhances RemeGen's investment narrative by extending its cash runway and reducing balance sheet risk. The focus now shifts to RC148's development and other key programs, while concerns about execution risk and high valuations remain. RemeGen's shares are seen as potentially undervalued by 14%, with community estimates suggesting a fair value of HK$114.07.</p>

The Bull Case For RemeGen (SEHK:9995) Could Change Following AbbVie’s RC148 Licensing Deal - Learn Why